SOPHiA GENETICS SA (NASDAQ:SOPH) Given Average Recommendation of “Hold” by Brokerages

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $10.00.

SOPH has been the subject of several recent analyst reports. HC Wainwright increased their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st.

SOPHiA GENETICS Stock Down 0.9%

Shares of SOPHiA GENETICS stock opened at $7.61 on Friday. The stock has a market cap of $638.40 million, a PE ratio of -6.62 and a beta of 0.98. SOPHiA GENETICS has a 12 month low of $3.10 and a 12 month high of $8.98. The business has a fifty day simple moving average of $6.98 and a 200 day simple moving average of $5.67. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Research analysts predict that SOPHiA GENETICS will post -0.77 EPS for the current year.

Insider Activity

In other news, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the transaction, the chief executive officer directly owned 3,601,493 shares of the company’s stock, valued at $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the transaction, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 342,592 shares of company stock worth $2,205,587 over the last three months. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth $49,000. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at $54,000. XTX Topco Ltd bought a new position in SOPHiA GENETICS during the 4th quarter worth $55,000. Finally, Susquehanna International Group LLP bought a new position in shares of SOPHiA GENETICS during the third quarter worth about $88,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.